Urteste Expands Development of Innovative Diagnostic Projects
September 26, 2024 10:29 ET
|
Urteste S.A.
Urteste Expands Development of Innovative Diagnostic Projects Gdańsk, Poland – 26 SEPTEMBER 2024, 16:00 CET - Urteste S.A. (Warsaw Stock Exchange: URT), a biotechnology company...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
September 19, 2024 08:00 ET
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - Long-term Forecast to 2033
August 23, 2024 11:51 ET
|
Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Global Cancer Cachexia Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global cancer cachexia market is forecast to...
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
August 20, 2024 08:30 ET
|
AIM ImmunoTech Inc.
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 16, 2024 07:00 ET
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August...
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
August 13, 2024 08:00 ET
|
Autonomix Medical, Inc.
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source Positive 7-day topline results from first...
Pancreatic Cancer Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - FibroGen, OSE Immunotherapeutics, Panbela Therapeutics, Lokon Pharma, Helix Biopharma, Tvardi Therapeutics, BioNTech, XBiotech, Lumicell, CARsgen Ther
July 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 09, 2024 (GLOBE NEWSWIRE) -- Pancreatic Cancer Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - FibroGen, OSE Immunotherapeutics, Panbela Therapeutics,...
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024 10:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer...
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally....